Consensus AtriCure, Inc.

Stocks

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 19:54:26 12/06/2026 +04			5-day change	1st Jan Change
28.62 ^USD	+0.72%		+5.44%	-27.77%

06-10	AtriCure, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 08:40 AM
05-12	AtriCure, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:00 AM

Evolution of the Average Target: AtriCure, Inc.

Evolution of the Target Price: AtriCure, Inc.

Changes in Analyst Recommendations: AtriCure, Inc.

45.oaKc8vGcl0HuXImMYCuaznv0l3V7KlEGIOjGo-owUi8.6v3Jo8np9BeIGsPtBBzclz-4pxc6HTtVEZiQwbt8OX6T8_WXi-37KYM_3A~fc053bc65a11a94e6eba1ea7f698f4f3

Analysts' recommendations: AtriCure, Inc.

02-18	UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating	MT
02-18	Oppenheimer Downgrades AtriCure to Market Perform From Outperform	MT
02-11	AtriCure Shares Fall After JPMorgan Downgrade	MT
02-11	Top Midday Decliners	MT
02-11	JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48	MT
30/07/25	Needham Raises Price Target on AtriCure to $45 From $44, Keeps Buy Rating	MT
30/07/25	AtriCure Q2 revenue beats estimates	RE
30/04/25	UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating	MT
28/03/25	Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating	MT
13/02/25	Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating	MT
30/10/24	UBS Adjusts Price Target on AtriCure to $40 From $35, Maintains Buy Rating	MT
31/07/24	Needham Adjusts AtriCure's Price Target to $34 From $40, Keeps Buy Rating	MT
02/05/24	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT
23/04/24	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
16/02/24	UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	MT
16/02/24	Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	MT
16/02/24	Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	MT
22/01/24	UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	MT
23/10/23	JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	MT
29/09/23	UBS Initiates AtriCure With Buy Rating, Price Target is $56	MT
26/07/23	Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating	MT
03/05/23	Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating	MT
22/02/23	BTIG Lowers Price Target on AtriCure to $55 From $65, Maintains Buy Rating	MT
22/02/23	Stifel Adjusts Price Target on AtriCure to $48 From $55, Maintains Buy Rating	MT
22/02/23	Canaccord Genuity Adjusts Price Target on AtriCure to $74 From $81, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ATRICURE, INC.					+65.43%
	ABBOTT LABORATORIES					+30.83%
	MEDTRONIC PLC					+22.72%
	CENCORA, INC.					+24.55%
	HOYA CORPORATION					+17.4%
	BECTON, DICKINSON AND COMPANY					+22.99%
	MEDLINE INC.					+37.75%
	DEXCOM, INC.					+12.51%
	WEST PHARMACEUTICAL SERVICES, INC.					+8.61%
	TERUMO CORPORATION					+30.84%
	Average					+27.36%
	Weighted average by Cap.					+25.00%